Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...

The European Commission (EC) granted marketing authorization for Afqlir (aflibercept), which is a 2 mg vial kit and pre-filled syringe for intravitreal injection. This is a biosimilar to reference ...